A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Pediatrics Research -
Principal Investigator
-
Sponsor
Incyte
The overall goal of this study are to: Part 1 - Find the best dose of ruxolitinib to use with standard chemotherapy in children, adolescents, and young adults with HR B-ALL; Part 2 - Find out if the investigational drug ruxolitinib helps chemotherapy to work better and to compare the effects, good and/or bad, of using ruxolitinib with chemotherapy. Other goals of this study are to better understand the effects of ruxolitinib in children, adolescents, and young adults who have HR B-ALL.